Dr Nancy Y. Lee talks to ecancer at ASCO 2026 about long-term follow-up data on FMISO PET-guided radiation dose de-escalation in patients with HPV-associated oropharyngeal cancer.

The study found that patients without tumour hypoxia who received substantially lower-dose radiotherapy achieved comparable five-year overall survival, progression-free survival, and local and regional control to those receiving standard-dose treatment, supporting a personalised approach to radiation de-escalation.